MSCM
FOLD

McElhenny Sheffield Capital Management’s Amicus Therapeutics FOLD Stock Holding History

McElhenny Sheffield Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-69
Closed -$842 – 274
2022
Q4 		$842 Buy
+69
New +$777 ﹤0.01% 590

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

McElhenny Sheffield Capital Management's FOLD Position: Q1 2023 in Review

McElhenny Sheffield Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 69 shares — an estimated $842 sold.

McElhenny Sheffield Capital Management first reported a position in FOLD in Q4 2022 and held it in 1 quarter. The position peaked at $842 in Q4 2022. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

  • McElhenny Sheffield Capital Management reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • McElhenny Sheffield Capital Management sold 69 Amicus Therapeutics shares in Q1 2023, an estimated $842.
  • McElhenny Sheffield Capital Management first reported a position in Amicus Therapeutics in Q4 2022 and held it in 1 quarter.
  • McElhenny Sheffield Capital Management's Amicus Therapeutics position peaked at $842 in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on McElhenny Sheffield Capital Management's 13F filing for Q1 2023, filed 13 Apr 2023.